Phase 1 Dose‐Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers

por Miyoshi, So, Krishnaswami, Sriram, Toyoizumi, Shigeyuki, Nakamura, Hiroyuki, Zwillich, Samuel H.
Publicado 2019

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria

por Smolen, Josef S., Aletaha, Daniel, Gruben, David, Zwillich, Samuel H., Krishnaswami, Sriram, Mebus, Charles
Publicado 2017

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomiz...

por Strand, Vibeke, Kremer, Joel M., Gruben, David, Krishnaswami, Sriram, Zwillich, Samuel H., Wallenstein, Gene V.
Publicado 2017

Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review

por Mostaghimi, Arash, Napatalung, Lynne, Sikirica, Vanja, Winnette, Randall, Xenakis, Jason, Zwillich, Samuel H., Gorsh, Boris
Publicado 2021

Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database

por George, Prethibha, Jagun, Oladayo, Liu, Qing, Wentworth, Charles, Napatalung, Lynne, Wolk, Robert, Anway, Susan, Zwillich, Samuel H.
Publicado 2023

Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors

por Rendas-Baum, Regina, Wallenstein, Gene V, Koncz, Tamas, Kosinski, Mark, Yang, Min, Bradley, John, Zwillich, Samuel H
Publicado 2011

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

por Strand, Vibeke, Kremer, Joel, Wallenstein, Gene, Kanik, Keith S., Connell, Carol, Gruben, David, Zwillich, Samuel H., Fleischmann, Roy
Publicado 2015

Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis

por Jansen, Jeroen P., Vieira, Maria-Cecilia, Bradley, John D., Cappelleri, Joseph C., Zwillich, Samuel H., Wallenstein, Gene V.
Publicado 2016

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6

por van Vollenhoven, Ronald F., Lee, Eun Bong, Fallon, Lara, Zwillich, Samuel H., Wilkinson, Bethanie, Chapman, Douglass, DeMasi, Ryan, Keystone, Edward
Publicado 2018

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis

por Strand, Vibeke, van Vollenhoven, Ronald F., Lee, Eun Bong, Fleischmann, Roy, Zwillich, Samuel H., Gruben, David, Koncz, Tamas, Wilkinson, Bethanie, Wallenstein, Gene
Publicado 2016

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial

por Strand, Vibeke, Lee, Eun Bong, Fleischmann, Roy, Alten, Rieke E, Koncz, Tamas, Zwillich, Samuel H, Gruben, David, Wilkinson, Bethanie, Krishnaswami, Sriram, Wallenstein, Gene
Publicado 2016

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies

por Fleischmann, Roy, Kremer, Joel, Tanaka, Yoshiya, Gruben, David, Kanik, Keith, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene, Wilkinson, Bethanie, Zwillich, Samuel H., Keystone, Edward
Publicado 2016

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis

por Genovese, Mark C., van Vollenhoven, Ronald F., Wilkinson, Bethanie, Wang, Lisy, Zwillich, Samuel H., Gruben, David, Biswas, Pinaki, Riese, Richard, Takiya, Liza, Jones, Thomas V.
Publicado 2016